| Date | Rating | Target Price | Recommendation Price | Broker house |
| 6 May 2011 | hold | 2161 | 2288 | Emkay Report |
glaxosmithkline pharma (Emkay) Steady business momentum; Maintain Hold
Revenue growth led by traction across business units; EBITDA margins contraction led by higher raw material and other expenses; One-time provisioning dented bottom-line
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment